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Introduction
The Health Insurance Portability and Accountability Act of 1996 (HIPAA) required the
Secretary of Health and Human Services (HHS) to propose standards to protect the privacy of
individually identifiable health information by August 21, 1997.  On September 11, 1997, the
Secretary submitted a report to Congress recommending that Congress pass comprehensive privacy
legislation.  Under HIPAA, Congress was given two years (until August 21, 1999) to enact privacy
legislation.  If Congress failed to act by that date, HIPAA directed the Secretary to finalize
regulations containing proposed standards relating to the electronic transfer of medical information
by February 21, 2000.  Despite the statutory deadline, Congress was unable to reach consensus on
the numerous privacy bills introduced.  The Secretary of Health and Human Services then moved
forward as required by HIPAA to promulgate regulations.
On November 3, 1999, HHS published a proposed rule in the Federal Register (64 Fed. Reg.
59918) that detailed standards for the privacy of electronically transmitted individually identifiable
health information.  The proposed regulation was narrower than the Secretary’s 1997 legislative
recommendations, but was nevertheless broad in scope, protecting electronically exchanged medical
records and other personal health information maintained by health care providers, health plans,
health insurers and health care clearinghouses.
The Department received over 52,000 comments on the proposed privacy rule, which
demonstrated how significant these regulations were to those in the health care industry that use
patient medical information for a variety of purposes.  In addition, many individuals whose personal
medical information is the subject of the rule filed comments on the proposed protections.
Given the magnitude of the response, the Department was unable to meet its statutory
deadline under HIPAA to finalize regulations by February 21, 2000.  On December 20, 2000, HHS
released a comprehensive final regulation (the Privacy Rule).1
On February 26, 2001, the Department published a notice in the Federal Register
postponing the effective date of the Privacy Rule until April 14, 2001.2  The Department published
another notice on February 28, 2001 announcing that public comments on the final regulation
would be accepted for a limited period (until March 30, 2001) before the rule became effective.3
On April 14, 2001, the Privacy Rule became effective.  Despite speculation that HHS would
modify the rule prior to its effective date, the Bush Administration allowed the rule to take effect on
schedule.  HHS received approximately 11,000 new comments on the Privacy Rule during the
comment period that ended on March 30, 2001.4
                                      
1 A fact sheet on the final regulation prepared by the U.S. Department of Health and Human Services can be found at
http://aspe.hhs.gov/admnsimp/final/pvcfact2.htm.  The regulation itself is available electronically at
http://aspe.hhs.gov/admnsimp.
2 66 Fed. Reg. 12434 (Feb. 26, 2001).
3 66 Fed. Reg. 12738 (Feb. 28, 2001).
4 HHS noted the number of comments in a July 6, 2001 press release, which can be found at
http://hhs.gov/news/press/2001pres/20010706a.html.
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On July 6, 2001, HHS issued its first guidance on the Privacy Rule.5  The guidance addresses
specific topics in both a brief question-and-answer and detailed comment format.  The topics
covered include patient consent, parental rights, marketing, medical research, and governmental
access issues.  Some of these topics (and others) are noted herein where relevant.  The press release
also noted that HHS “expects to propose appropriate changes to the rule in order to ensure that it
does not adversely affect patients’ access to quality health care.”6  The guidance notes that in order
to make any changes, HHS must follow the notice-and-comment provisions of the Administrative
Procedures Act.7  These provisions require publication of the proposed changes in the Federal Register
and a period of public comment.
This Issue Brief provides an overview of and crosswalk between the Privacy Rule and the
federal Confidentiality of Alcohol and Drug Abuse Patient Records statute, 42 U.S.C. § 290dd-2, and
its implementing regulations at 42 C.F.R. Part 2 (“42 C.F.R. Part 2”).  The crosswalk is intended to
highlight the differences between the requirements of the Privacy Rule and 42 C.F.R. Part 2.  In
addition, this Issue Brief addresses the Privacy Rule’s applicability to special populations and
psychotherapy services provided by substance abuse paraprofessionals.
The Privacy Rule
General Rule
In general, the Privacy Rule can be summarized as follows:  “Covered entities” may not use
or disclose “protected health information” (PHI) except as authorized by the individual who is the
subject of the information, or as explicitly required or permitted by the regulation.8
Even when the use or disclosure of PHI is permitted, in most circumstances, only the
“minimum necessary” amount of information to accomplish the intended purpose of the use,
disclosure or request may be provided.
The rules apply to all protected health information maintained, used or disclosed by a
covered entity, regardless of the form it takes – electronic, written or oral.  This information remains
protected during the life of the individual, and information about a deceased individual must remain
protected as long as the covered entity maintains the information.
Key Definitions
Covered entities
“Covered entities” are broadly defined.9  The term includes:
                                      
5 The guidance can be found at http://aspe.hhs.gov/admnsimp/final/pvcguide1.htm.  As an example of the changes
HHS will propose, the press release cites “modifications to ensure that a pharmacist can fill a phoned-in prescription for
a new patient, even when the pharmacist does not first have the patient’s signed consent on file.”  Id.
6 See the July 6, 2001press release at http://hhs.gov/news/press/2001pres/20010706a.html.
7 Id.
8 45 CFR § 164.502(a), 65 Fed. Reg. 82805 (Dec. 28, 2000).
9 45 CFR § 160.103, 65 Fed. Reg. 82799 (Dec. 28, 2000).
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• A health plan;
• A health care clearinghouse; and
• A health care provider who transmits health information in electronic form in
connection with transactions (i.e., exchanges of information) covered by HIPAA’s
administrative requirements
 Health plan
A “health plan” means an individual or group plan that provides, or pays the cost of, medical
care (as defined in §2791(a)(2) of the Public Health Service Act (PHSA)). Health plans include:10
• Virtually all group health plans (insured or self-insured) covered under the Employee
Retirement Income Security Act of 1974 (ERISA) (i.e, those group health plans with
50 or more participants and plans of any size that are administered by other entities);
• Health insurance issuers (as defined by HIPAA to include an insurance company,
insurance services, or insurance organization (including a health maintenance
organization) that is licensed to engage in the business of insurance in a state and





• Medicare-supplemental policy issuers;
• An employee welfare benefit plan or any other arrangement providing health
benefits to employees of two or more employers;
• MEWAs (multiple employer welfare arrangements);
• Health care programs for active military personnel and veterans;
• CHAMPUS;
• The Indian Health Service;
• The Federal Employees Health Benefit Program;
• Approved SCHIP programs;
• Medicare +Choice plans; and
• State high-risk pools.
Health care clearinghouse11
“Health care clearinghouses” are public or private entities (including billing companies or
community health management information systems) that either (1) process or facilitate processing
of health information received from another entity in a nonstandard format into standard data
elements or a standard transaction; or (2) receive a standard transaction from another entity and
process or facilitate processing of health information into a nonstandard format or nonstandard data
content for the receiving entity.
Health care provider12
                                      
10  Id.
11 45 C.F.R. § 160.103, 65 Fed. Reg. 82799 (Dec. 28, 2000).
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“Health care providers” are providers of medical or health services and any other person or
organization that furnishes, bills or is paid for health care in the normal course of business.
Health care13
“Health care” includes preventive, diagnostic, therapeutic, rehabilitative, maintenance, or
palliative care.  It also includes counseling, service, assessment, or other procedure with respect to
the physical or mental condition (or functional status) of an individual or that affects the structure or
function of the body.
Protected health information (PHI)14
“Protected health information (PHI)” means individually identifiable health information that
is transmitted or maintained by electronic media or is transmitted or maintain in any other form or
medium.
“Health information” is any information (whether oral or recorded in any form or medium)
that is created or received by a health care provider, health plan, public heath authority, employer,
life insurer, school or university, or health care clearinghouse and relates to the past, present or
future physical or mental health or condition of an individual, the provision of health care to an
individual or the past, present or future payment for the provision of health care to an individual.15
This definition reflects the broad category of information governed by the administrative
simplification provisions of HIPAA.
“Individually identifiable health information” is a subset of “health information.”  It is health
information that either actually identifies the individual or creates a reasonable basis to believe that
the information would identify the individual.16
As defined above, PHI is a subset of individually identifiable health information.  Note that
the protections described below apply to data or information about an individual, not to any
particular record.  However, once the privacy protections attach to data, the transmitter and receiver
of the data must protect every record (written, electronic or other) in which the data appears.
Disclosure of Protected Health Information
General rule
Under the Privacy Rule, covered entities may use or disclose PHI only:
• with the consent or authorization of the patient; or
• as explicitly permitted or required by the regulation.
                                                                                                                          
12 45 CFR § 160.103, 65 Fed. Reg. 82799 (Dec. 28, 2000).
13 Id.
14 45 CFR § 164.501, 65 Fed. Reg. 82805 (Dec. 28, 2000).
15 45 CFR § 160.103, 65 Fed. Reg. 82799 (Dec. 28, 2000).
16 45 CFR § 164.501, 65 Fed. Reg. 82803 (Dec. 28, 2000).
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In addition, individuals have certain rights to their own health information (described
below).
Consent v. authorization
Although most people use the terms “consent” and “authorization” interchangeably, the
Privacy Rule makes an important distinction between them.17
As described in more detail below, “consent” refers to a broad general permission granted
by the individual to a health care provider or other covered entity to use or disclose the individual’s
PHI for treatment, payment or health care operations purposes. 18
Different covered entities have different obligations regarding general consents.  For
example, providers are required to get a signed consent from the patient in order to release PHI to
another covered entity or business partner for treatment, payment, and healthcare operations.
Health insurers, however, are not required to obtain a general consent to release PHI to covered
entities or business partners for such routine operations.   A covered entity cannot use a general
“consent” by an individual to share PHI with a non-covered entity or non-business partner.
In contrast, an “authorization” refers to a more specific and detailed permission given to a
covered or non-covered entity or business partner by an individual to share an individual’s PHI
about issues other than treatment, payment, and healthcare operations.  All covered entities,
including health insurers, providers, health care clearinghouses are required to obtain authorization
for the disclosure of PHI for purposes other than routine operations.
In general, the Privacy Rule permits covered entities to use or disclose PHI for treatment,
payment or health care operations.  Each of these terms is discussed below.  The rule contains some
specific restrictions on those and other uses and disclosures of PHI.
For example, patient consent is necessary for providers to use or disclose PHI for treatment,
payment or health care operations.  In the case of other covered entities, disclosures are generally
permitted for those uses without consent.  A covered entity is only permitted to disclose PHI for
other purposes with individual authorization.
Patient Consent for Uses or Disclosure of Routine Operations
A covered health care provider must obtain the individual’s consent prior to using the
individual’s PHI for treatment, payment or health care operations (each of these terms is described
below).  For example, consent is necessary unless the provider:
• has an indirect treatment relationship19 with the individual,
                                      
17 The provisions governing “consent” are generally found in 45 CFR § 164.506 and the provisions governing
“authorization” are generally found in 45 CFR § 164.508.
18 For ease of reference, this analysis often refers to health care treatment, payment, and operations as “routine
operations.”  The terms “routine operations” and “treatment, payment, and operations” are interchangeable.
8
• is providing health care to an inmate,
• is in an emergency treatment situation (but then the provider must attempt to obtain
consent as soon as practicable after the treatment is delivered),
• is required by law to obtain consent but unable to do so, or
• is unable to obtain consent because of substantial communication barriers.20
Patient Authorization for Disclosure of Non-Routine Operations
Unless otherwise specified under the regulation, a covered entity may only use or disclose
PHI when it receives a valid authorization by an individual.  Any use or disclosure of PHI must be
consistent with the authorization.21
Except in certain circumstances, authorization is required for use or disclosure of
psychotherapy notes, which will be discussed more fully below.22
Valid authorizations
To be valid, an authorization by the individual must:
• Describe the information to be used or disclosed in a specific and meaningful
fashion;
• Name the person or class of persons authorized to make the disclosure or use;
• Name the person or class of persons to whom the disclosure may be made;
• Contain an expiration date that relates to the individual or to the purpose of the
disclosure or use;
• Clearly state that the individual has a right to revoke the authorization in writing (and
describe the procedure for doing so) as well as any exemptions to the right to revoke;
• Be signed by the individual (or the individual’s personal representative) and dated.
The authorization must be written in plain language.  In addition, if the proposed disclosure
of PHI will be to a non-covered entity, the authorization must clearly state that the individual
understands that disclosure to non-covered entities removes any privacy protections that had
attached to the PHI.23
If a covered entity initiates the request for authorization for disclosure, rather than the
individual, certain additional requirements are imposed beyond those described above.
Among the further requirements are:
                                                                                                                          
19 An “indirect treatment relationship” means a relationship between an individual and a health care provider in which
(1) the health care provider delivers health care to the individual based on the orders of another health care provider, and
(2) the health care provider typically provides services, products or reports (e.g., diagnosis) directly to another health care
provider who then provides the services or products or reports to the individual.  45 C.F.R. § 164.501; 65 Fed. Reg.
82804 (Dec. 28, 2000).
20 45 CFR § 164.506, 65 Fed. Reg. 82810 (Dec. 28, 2000).
21 45 CFR § 164.508, 65 Fed. Reg. 82811 (Dec. 28, 2000).
22 45 CFR § 164.508(a)(2), 65 Fed. Reg. 82811 (Dec. 28, 2000).
23 45 CFR § 164.508(c), 65 Fed. Reg. 82811-12 (Dec. 28, 2000).
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1. the covered entity must specify the purposes for which the information is requested and
how it will be used so that the individual can make an informed judgment whether or
not to consent to the disclosure;
2. the request is subject to the “minimum necessary” requirements, described above;
3. individuals must be advised that they have a right to inspect and copy the information to
be used or disclosed and that they have a right to refuse to authorize the requested use
or disclosure;
4. treatment, payment, enrollment in the health plan, or eligibility for benefits cannot be
conditioned on the individual’s authorization; and
5. if the covered entity will be receiving direct or indirect financial compensation in
exchange for using or disclosing the PHI, the authorization must state that disclosure
would result in such compensation to the covered entity.
The individual must be given a copy of the signed authorization.24
Note that general waivers of confidentiality of a patient’s medical information that often
appear on enrollment or claims forms would no longer be valid under this regulation.
Required Disclosures/Disclosures Without Consent25
Covered entities are required to disclose PHI regarding an individual only in two instances:
(1) to the individual who is the subject of the PHI when the individual requests it, and (2) to the
Secretary of Health and Human Services when the Secretary is investigating a complaint or
determining a covered entity’s compliance with the regulation.  A description of the rights of access
to PHI for individuals is found in §164.524 (45 Fed. Reg. 82823-24) and an individual’s right to an
accounting of disclosures of PHI in §164.528 (45 Fed. Reg. 82826).
Permitted uses and disclosures26
The proposed regulations permit use or disclosure of PHI only in the following
circumstances:
• To the patient (required disclosure if requested);
• Pursuant to a valid consent by the patient that meets the requirements of the regulation
to carry out treatment, payment or health care operations;
• Pursuant to a valid authorization by the patient that meets the requirements of  the
regulation;
• Pursuant to an agreement under, or as otherwise permitted by, the regulation; or
                                      
24 45 CFR § 164.508(d), 65 Fed. Reg. 82812 (Dec. 28, 2000).
25 45 CFR § 164.502(a)(2), 65 Fed. Reg. 82805 (Dec. 28, 2000).
26 45 CFR § 164.502(a)(1), 65 Fed. Reg. 82805 (Dec. 28, 2000).
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• As explicitly permitted or required by the regulation (e.g., to the Secretary of HHS for
purposes of determining compliance with the rule).
“Treatment” means the provision, coordination, or management of health care and related
services by one or more health care providers.  It also includes coordination or management of
health care by a health provider and a third-party and consultation or referrals between one health
care provider and another.27
“Payment” includes activities undertaken by a health plan or provider to obtain or provide
reimbursement or premiums for the provision of health care and other activities, such as
determinations of eligibility or coverage (including coordination of benefits), risk adjustments,
billing, claims management, collections, medical necessity reviews, and utilization review.28
“Health care operations” includes certain services or activities necessary to carry out the
covered functions of the covered entity with respect to treatment or payment, such as conducting
quality assessment and improvement activities, outcomes evaluation and development of clinical
guidelines (providing that obtaining generalizable knowledge is not the primary purpose of any
studies resulting from these activities), population-based activities related to improving health or
reducing health care costs, coordinating or managing care,  evaluating provider performance,
engaging in accreditation, certification or licensing activities, underwriting or premium rating for
purposes of creation, renewal, or replacement of a contract of health insurance or health benefits,
conducting or arranging for medical review, legal services, and auditing (including detection of fraud
and abuse), business planning or development, management activities, customer service, resolution
of internal plan grievances, and due diligence in connection with the sale or transfer of assets to a
potential successor in interest.29   Auditing claims and deciding claims appeals are two common plan
functions that are included as part of health care operations.
In addition, §164.512 of the final regulation describes a number of situations in which
covered entities may disclose the PHI of an individual without the individual’s written consent.30
Unless a covered entity is specifically required to disclosure PHI without the individual’s consent
(e.g., for health care oversight), however, the permission to disclose PHI without consent does not
require such disclosure.  For instance, these disclosures may be made:
(1) to the extent that the disclosure is required by law and the use or disclosure
complies with and is limited to the relevant requirements of that law;31
(2) for certain public health activities.32  These might include disclosure to:
• a public health authority authorized by law to collect information to
prevent or control disease or conduct public health surveillance;
                                      
27 45 CFR § 164.501, 65 Fed. Reg. 82805 (Dec. 28, 2000).
28 45 CFR § 164.501, 65 Fed. Reg. 82804-05 (Dec. 28, 2000).
29 45 CFR § 164.501, 65 Fed. Reg. 82803 (Dec. 28, 2000).
30 45 CFR § 164.512, 65 Fed. Reg. 82813-18 (Dec. 28, 2000).
31 45 CFR § 164.512(a), 65 Fed. Reg. 82813 (Dec. 28, 2000).
32 45 CFR § 164.512(b), 65 Fed. Reg. 82813-14 (Dec. 28, 2000).
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• a public health authority empowered by law to receive reports of child
abuse or neglect;
• under certain circumstances, to a person subject to the jurisdiction of
the Food and Drug Administration (FDA);
• a person exposed to a communicable disease; or
• in certain circumstances, an employer regarding workplace-related
medical surveillance activities.
(3) to a government authority authorized by law when the covered entity
reasonably believes that an individual is a victim or abuse, neglect or
domestic violence;33
(4) for health oversight activities authorized by law, including, for instance, fraud
and abuse audits, investigations, and civil, administrative, or criminal
proceedings (except if the investigation or other activities does not arise out
of and is not directly related to the receipt of health care or qualification or
receipt of public health benefits or services);34
(5) for judicial and administrative proceedings under certain circumstances;35
(6) for law enforcement purposes to a law enforcement official.  However,
under this exception, only limited information may be disclosed for
identification and location purposes, such as information about an individual
who is a victim of a crime when the victim has agreed to the disclosure or
when reporting a crime in an emergency;36
(7) to organ procurement organizations regarding cadaver organs, eyes, or tissue
for donation purposes;37
(8) for research purposes provided that an Institutional Review Board (IRB) or
privacy board (as described in §164.512(i)(B) of the regulation) approves the
waiver of individual authorization required under §164.508 of the regulation
and certain other conditions are met;38
(9) to avert a serious threat to health or safety;39
(10) for specialized government functions, such as separation or discharge from
the military, to determine eligibility for veterans’ health benefits, or for
protective services for the President and others;40
                                      
33 45 CFR § 164.512(c), 65 Fed. Reg. 82814 (Dec. 28, 2000).
34 45 CFR § 164.512(d), 65 Fed. Reg. 82814 (Dec. 28, 2000).
35 45 CFR § 164.512(e), 65 Fed. Reg. 82814-15 (Dec. 28, 2000).
36 45 CFR § 164.512(f), 65 Fed. Reg. 82815-16 (Dec. 28, 2000).
37 45 CFR § 164.512(h), 65 Fed. Reg. 82816 (Dec. 28, 2000).
38 45 CFR § 164.512(i), 65 Fed. Reg. 82816-17 (Dec. 28, 2000).
39 45 CFR § 164.512(j), 65 Fed. Reg. 82817 (Dec. 28, 2000).
40 45 CFR § 164.512(k), 65 Fed. Reg. 82817-18 (Dec. 28, 2000).
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(11) to the extent necessary to comply with workers’ compensation or other
similar laws.41 Note that the exception permitting disclosure applies only
when providing the information is required under these laws, not when the
laws simply permit disclosure.
Minimum Necessary42
Even if the covered entity is authorized to use or disclose PHI, it must make reasonable
efforts to limit PHI to the minimum amount of PHI necessary to accomplish the intended purpose
of the use or disclosure.  The “minimum necessary” standard does not apply to:
• disclosures to or requests for information by a health care provider for
treatment,
• certain disclosures made to an individual who is the subject of the PHI or to the
Secretary of HHS,
• to uses or disclosures required by law, or
• to uses or disclosures that are required for compliance with the regulation.
As a practical matter, the “minimum necessary” determination should begin with an
assessment of whether or not the intended use or purpose could be accomplished by de-identifying
the data or using summary data, rather than assuming that all protected health information may be
disclosed, and then attempting to narrowing the scope of disclosure of PHI to comply with the
minimum necessary rule.
Disclosures to business associates
The Privacy Rules also applies to transactions between covered entities and their “business
associates.”  Business associates are defined as those who perform or assist in the performance by a
covered entity of:
(1) a function or activity involving the use or disclosure of individually
identifiable health information (including claims processing or administration,
data analysis, quality assurance, billing, benefit management);
(2) a function or activity regulated by HIPAA.
Business associates are persons who provide certain services to or on behalf of the covered
entity, including legal, actuarial, accounting, consulting, data aggregation, management,
administrative, accreditation or financial services.43
                                      
41 45 CFR § 164.512(l), 65 Fed. Reg. 82818 (Dec. 28, 2000).
42 45 CFR § 164.502(b), 65 Fed. Reg. 82805 (Dec. 28, 2000).
43 45 CFR § 160.103, 65 Fed. Reg. 82798 (Dec. 28, 2000).
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Generally speaking, covered entities may only share information with business associates
pursuant to a contract that limits the use and disclosure of protected health information (PHI) under
the same restrictions that apply to the covered entity.
A contract between a covered entity and its business associate(s) must meet the requirements
of §164.504((e)(2) or (e)(3).44  Among other things, this contract must:
(1) set out the permitted and required uses and disclosures of PHI by the business
associate;
(2) provide that the business associate will:
(a) not use or further disclose PHI except as permitted by the regulation:
(b) use appropriate safeguards to assure the proper use of PHI;
(c) report to the covered entity any inappropriate or non-contractually agreed
upon use of PHI of which it becomes aware;
(d) ensure that its employees, agents, and subcontractors agree to the same
restrictions that are imposed on the business associate; and
(e) permit the Secretary and the covered entity access for audit purposes to its
internal practices, books and records relating to the use or disclosure of PHI.
If the covered entity and its business associate(s) are both governmental entities, these
requirements can be satisfied through a Memorandum of Understanding, rather than a contract.45
Rights of Individuals
The Privacy Rule affords new rights to individuals regarding access to their own PHI.  For
instance, individuals have a right to:
• inspect and obtain a copy of all PHI relating to the individual;46
• amend and/or correct that PHI;47
• with certain exceptions, an accounting of the uses and disclosure of their PHI
(i.e., to know when and to whom disclosure has been made for purposes other
than treatment, payment and health operations, including disclosures made by or
                                      
44 45 CFR § 164.504(e)(1), 65 Fed. Reg. 82808 (Dec. 28, 2000).
45 45 CFR § 164.504(e)(3), 65 Fed. Reg. 82808 (Dec. 28, 2000).
46 There are three exceptions to this rule.  Individuals do not have a right of access to:  (1) psychotherapy notes, (2)
information compiled in reasonable anticipation of, or for use in, a civil, criminal or administrative action or proceeding,
and (3) certain protected health information maintained by a covered entity that is subject to or exempted from the
Clinical Laboratory Improvements Amendments of 1988 (CLIA). 45 CFR § 165.524(a), 65 Fed. Reg. 82823 (Dec. 28,
2000).
47 45 CFR § 164.526, 65 Fed. Reg. 82824-26 (Dec. 28, 2000).
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to a business associate); this right applies to disclosures made in the six (6) year
period prior to the request for an accounting;48
• notice49 and a full description of the covered entity’s use and disclosure practices
(generally any use or disclosure of PHI not described in this notice is
prohibited);50 and
• challenge the covered entity’s use or disclosure of PHI through complaints to (1)
the privacy official designated by each covered entity and through the complaint
process that must also be established or (2) to the Secretary of HHS through a
process that the Secretary will establish.51
Preemption of State Privacy Laws
The Privacy Rule does not save state statutes that would otherwise be preempted by ERISA,
but the statute and rule do leave in place more stringent state privacy protections.  The regulation
specifically states that:
[O]ur reading of the statutes together is that the effect of section
264(c)(2) [of HIPAA] is only to leave in place state privacy
protections that would otherwise apply and that are more stringent
than the federal privacy protections.52
“More stringent” state laws are defined in the regulation as those that are more protective of
an individual’s right to privacy protection for his or her PHI, including those state laws providing for
greater rights of access or amendment to individuals or prohibiting or restricting a disclosure or use
under circumstances in which the Privacy Rule permits it.53
                                      
48 45 CFR § 164.528, 65 Fed. Reg. 82826 (Dec. 28, 2000).  Covered entities must provide this information within a
reasonable time after the request is made, generally no later than 60 days following the receipt of the request, although
under certain circumstances, extensions may be allowed.
49 Individuals must be given a plain-language written notice of the covered entity’s practices and procedures regarding
PHI.  Generally the notice must describe what is done with their PHI, how it is safeguarded, and what rights individuals
have with respect to that information, including the right to inspect and copy PHI. The notice must also identify the
covered entity’s privacy officer and, if different, a contact person for registering complaints and obtaining additional
information.  The notice must be distributed by the compliance date of the final regulation or, if later, at enrollment.  In
addition, the notice must be distributed at least once every three years thereafter. If a covered entity materially changes
its procedures, it must update the notice and redistribute it within 60 days of the change. 45 CFR § 164.520, 65 Fed. Reg.
82820-22 (Dec. 28, 2000).
50 45 CFR § 164.520, 65 Fed. Reg. 82820-22, and 45 CFR § 164.530(i), 65 Fed. Reg. 82827 (Dec. 28, 2000).
51 45 CFR § 164.530(d), 65 Fed. Reg. 82825 (complaints to covered entity) and 45 CFR § 160.306, 308, 310, and 312, 65
Fed. Reg. 82801-02 (complaints to the Secretary) (Dec. 28, 2000).
52 Preamble, 65 Fed. Reg. 82483 (Dec. 28, 2000).
53 45 CFR § 160.202, 65 Fed. Reg. 82800-01 (Dec. 28, 2000).
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Applicability to Special Populations:  Victims of Abuse, Neglect, or Domestic Violence
The Privacy Rule allows covered entities to use or disclose PHI without consent or authorization
if the covered entity reasonably believes the patient is a victim of abuse, neglect, or domestic
violence.54  The rule covers child abuse55 and other victims of abuse, neglect or domestic violence
(e.g., abuse of nursing home residents or residents of facilities for the mentally retarded).
Covered entities can make such disclosures only to a government authority, including a social
service or protective services agency, authorized by law to receive reports of such abuse, neglect, or
domestic violence.56  The disclosure can be made only if:
• the disclosure is required by law and complies with and is limited to the relevant
requirements of such law;  or
• if the individual agrees to the disclosure; or
• to the extent the disclosure is expressly authorized by statute or regulation and
1. the covered entity, in its professional judgment, believes the disclosure is necessary
to prevent serious harm to the individual or other potential victims; or
2. if the individual is unable to agree because of incapacity, a law enforcement or other
public official authorized to receive the report represents that the PHI sought is not
intended for use against the individual and that an immediate enforcement activity
that depends upon the disclosure would be materially and adversely affected by
waiting until the individual is able to agree to the disclosure.57
Once the covered entity discloses the PHI, it must promptly inform the individual that a
report has been made, unless:
• the covered entity, in the exercise of professional judgment, believes that informing the
individual would place the individual at risk of serious harm; or
• the covered entity would be informing a personal representative, and the covered entity
reasonably believes the personal representative is responsible for the abuse, neglect, or
other injury, and that informing the representative would not be in the best interests of
the individual.58
Psychotherapy Services Provided by Substance Abuse Paraprofessionals
The privacy rule treats psychotherapy notes as a distinct category of PHI.  With a few
exceptions, covered entities must obtain an individual’s authorization to use or disclose
                                      
54 45 C.F.R. § 164.512(c), 65 Fed. Reg. 82814 (Dec. 28, 2000).





psychotherapy notes to carry out treatment, payment, or health care operations.59  As a practical
matter, such authorizations will rarely be necessary, since, as the preamble to the rule points out,
psychotherapy notes do not include information that covered entities typically need for treatment,
payment, or other routine health care operations.60
A covered entity must obtain the patient’s consent (but not authorization) for the person
who created the psychotherapy notes to use the notes to carry out treatment and for the covered
entity to use or disclose psychotherapy notes for conducting training programs in which students,
trainees, or practitioners in mental health learn under supervision to improve their skills in
counseling.61
A covered entity may also use psychotherapy notes to defend a legal action or other
proceeding brought by the individual pursuant to a consent (but without a specific authorization).
This would allow disclosure to the covered entity’s attorney to defend against the action or
proceeding, but disclosure to others during the judicial or administrative proceeding is governed by
45 C.F.R. § 164.512(e) (which describes court orders compelling discovery of the notes, etc.).  The
rule’s preamble notes that disclosure to a covered entity’s attorney only requires consent because the
defense constitutes “health care operations” and the entity should be able to defend itself without
seeking a specific authorization from the patient.62
The rule does not explicitly address psychotherapy paraprofessionals.  The rule’s broad
definition, however, suggests that notes of paraprofessionals are treated similarly to those of any
other provider who is a mental health professional:
Psychotherapy Notes63
Notes recorded (in any medium) by a health care provider who is a mental health professional
documenting or analyzing the contents of a conversation during a private counseling session or a
group, joint, or family counseling session and that are separated from the rest of the individual’s
medical record.  Psychotherapy notes excludes medication prescription and monitoring, counseling
session start and stop times, the modalities and frequencies of treatment furnished, results of clinical
tests, and any summary of the following items: diagnosis, functional status, the treatment plan,
symptoms, prognosis, and progress to date.
Enforcement and Compliance
The Secretary of HHS delegated the enforcement of the Privacy Rule to HHS’s Office of
Civil Rights.  Through that office, the Secretary of HHS can bring enforcement actions against
covered entities.  Under HIPAA, the Secretary may impose civil monetary penalties of not more
than $100 per person per violation and up to $25,000 for violations of a single standard within a
single calendar year.  In addition, criminal penalties are established under HIPAA for wrongful
                                      
59 45 C.F.R. § 164.508(a)(2); 65 Fed. Reg. 82811 (Dec. 28, 2000).
60 65 Fed. Reg. 82515 (Dec. 28, 2000).
61 Id.
62 65 Fed. Reg. 82515 (Dec. 28, 2000).
63 65 Fed. Reg. 82805 (Dec. 28, 2000).
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disclosures of PHI, which, upon conviction, could result in fines of not more than $50,000 and/or
imprisonment for not more than one year.  Offenses committed with intent to sell, transfer or use
PHI for commercial or personal gain or malicious harm are punishable by a fine not to exceed
$250,000 and/or 10-year imprisonment.
The Privacy Rule does not authorize private rights of action for wrongful disclosure
violations.  However, individuals may report violations to the Secretary so HHS can undertake
appropriate investigation and enforcement activities on behalf of an aggrieved individual.64
Under the rule, providers have until April 14, 2003 to come into compliance (and small
health plans with less than five million in revenues have an additional year).65
42 C.F.R. Part 2
General Rule/History
In general, the confidentiality of alcohol and drug abuse patient records is regulated under 42
C.F.R. Part 2.  Because dependence on alcohol and drugs is not understood as a disease, there is a
stigma associated with addiction and addiction recovery.  People in recovery from addiction too
often suffer degradation and discrimination.  Many people in the public do not understand that
individuals in recovery are managing a chronic, relapsing disease, much like diabetes, and are not
“weak-willed” and “immoral.”  Because of the stigma associated with seeking assistance through an
alcohol and drug abuse prevention and treatment program, Congress passed the Confidentiality of
Alcohol and Drug Abuse Patient Records statute to encourage people to seek out and remain in
treatment and to protect the patient records of these individuals.
42 C.F.R. Part 2 prohibits the disclosure and use of drug and alcohol abuse records
maintained in connection with the performance of any federally assisted substance abuse program
unless certain conditions, addressed below, exist.66
Although 42 C.F.R. Part 2 permits disclosure in certain circumstances (with or without
consent), it does not require disclosure under any circumstances (although a court order can require
disclosure).  42 C.F.R. Part 2 is intended to ensure that a substance abuse patient in a federally
assisted alcohol or drug abuse program is “not made more vulnerable by reason of the availability of
his or her patient record than an individual who has an alcohol or drug problem and who does not
seek treatment.”67
In general, 42 C.F.R. Part 2 can be summarized as follows: the rule restricts the disclosure or
use of any information, whether or not recorded, that would identify a patient as a substance abuse
patient either directly, by reference to other publicly available information, or through verification of
such identification by another person.  The prohibition applies to information obtained by a
                                      
64 45 CFR §§ 160.306 and 160.312, 65 Fed. Reg. 82801-02 (Dec. 28, 2000).
65 66 Fed. Reg. 12434 (Feb. 26, 2001).
66 See 42 C.F.R. §2.3(a).
67 42 C.F.R. §2.3(b)(2).
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federally assisted alcohol or drug abuse program for the purpose of treating alcohol or drug abuse,
making a diagnosis for such treatment, or making a referral for such treatment.68
Key Definitions
Federally Assisted69
An alcohol or substance abuse program is considered to be federally assisted under 42
C.F.R. Part 2 if it:
• receives Federal funds in any form (e.g., Medicare or Medicaid) for any purpose
(including purposes not related to alcohol and drug treatment);
• holds Federal tax-exempt status, i.e., 501 3(c) tax-exempt status,  or allows for tax
deductions for contributions through the Internal Revenue Service.
• is conducted directly by the Federal government (e.g., an Federal agency’s employee
assistance program);
• a state or local government which receives Federal funds that may or may not necessarily
be spent for alcohol or drug abuse programs;
• receives SAPT grant funds that may or may not be supplemented by State or local funds;
and
• a program carried out under licensure, certification, registration or authorization by any
federal agency (e.g., provider status under Medicare or registration to dispense controlled
substances).
Substance Abuse Program70
Coverage includes, but is not limited to, treatment and rehabilitation programs, employee
assistance programs, programs within general hospitals, school-based programs, and private
practitioners that hold themselves out as providing, and that do provide, alcohol or drug abuse
diagnosis, treatment, or referral for treatment.
Disclose or Disclosure71
A communication of patient identifying information, the affirmative verification of another
person’s communication of patient identifying information, or the communication of any
information from the record of a patient who has been identified.
                                      
68 42 C.F.R. §2.12(a)(i)-(ii).
69 42 C.F.R. §2.12(b).
70 42 C.F.R. §2.12(e)(1).
71 42 C.F.R. §2.11.
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Patient 72
Any individual who has applied for, or has been given, a diagnosis for treatment for alcohol
or drug abuse at a federally assisted program.  This includes any individual who, after arrest on a
criminal charge, is identified as an individual with a potential alcohol or drug abuse program in order
to determine the individual’s eligibility to participate in a treatment program.
Patient Identifying Information73
The name, address, social security number, fingerprints, photograph, or similar information
by which the identity of a patient can be determined with reasonable accuracy and speed either
directly or with reference to other publicly available information.  The term does not include a
number assigned to a patient by a program, if that number does not consist of, or contain numbers
(such as social security, or driver’s license number) that could be used to identify a patient with
reasonable accuracy and speed from sources external to the program.
Qualified Service Organization74
A person or any entity (including corporations and government agencies) that provides
services to a program, such as data processing, bill collecting, dosage preparation, laboratory
analysis, or legal, medical, accounting, or other professional services, or services to prevent or treat
child abuse or neglect that:
(1) has entered into a written agreement with a program under which the person or
entity:
• acknowledges that in receiving, storing, processing or otherwise dealing with any
patient records from the program, it is fully bound by 42 C.F.R. Part 2; and
• if necessary, will resist in judicial proceedings any efforts to obtain access to
patient records except as permitted by 42 C.F.R. Part 2.
Records75
Any information, whether recorded or not, relating to a patient received or acquired by a
federally assisted alcohol or drug program.
Disclosure and Use of Substance Abuse Records
Under 42 C.F.R. Part 2, substance abuse records may be disclosed or used only as permitted
by the regulation (described below) and may not otherwise be disclosed or used in any civil, criminal,
administrative, or legislative proceedings conducted by any federal, state, or local authority.76





76 42 C.F.R. § 2.13(a).
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The regulation applies whether or not the person holding the information believes that the
person seeking the information already has it, has other means of obtaining it, is a law enforcement
official or other official, or has a subpoena, or any other justification for a disclosure or use that is
not permitted by 42 C.F.R. Part 2.77
In addition, a program may not respond to requests to acknowledge the presence of an
identified patient in a facility or part of a facility that is publicly identified as a substance abuse
facility unless the patient consents in writing to such acknowledgement or a court order compels
such acknowledgement.78  Responses to such requests for acknowledgement must be made in a
manner that does not reveal whether an identified individual has been or is being treated for
substance abuse.79
Permitted Disclosures With Patient Consent & Form of Consent80
A program may disclosure a patient’s records with the patient’s written consent to any
individual or organization named in the consent.81
A program may also disclose patient records to a central registry or to any detoxification or
maintenance treatment program within 200 miles for the purpose of preventing multiple enrollment
of the patient.82  Such a disclosure requires a patient’s written consent.  The disclosure may be made
when:
(1) the disclosure is made when the patient is accepted for treatment;
(2) the type or dosage of the drug is changed; or
(3) the treatment is interrupted, resumed, or terminated.
Such a disclosure must be limited to the patient’s identifying information, the type and dosage of the
drug, and relevant dates.  A central registry or detoxification program can use the information only
for the purpose of preventing multiple enrollments, and cannot redisclose the information or use the
information for any other purpose unless authorized by a court order.83
A program may also disclose information about a patient to elements of the criminal justice
system that have referred patients to the program and made the patient’s participation in the
program a condition of the disposition of any criminal proceedings.84  Such a disclosure can be made
if (1) it is made only to the individuals within the criminal justice system that need the information in
connection with their duty to monitor the patient’s progress (e.g., probation or parole officers); and
(2) the patient has signed a written consent for the disclosure.
                                      
77 Id.
78 42 C.F.R. § 2.13(b).
79 Id.
80 42 C.F.R. § 2.33.
81 Disclosures to central registries and in connection with criminal justice activities must meet the other requirements of
the regulation.  See 42 C.F.R. § 2.34 and § 2.35, respectively.
82 42 C.F.R. § 2.34.
83 Id.
84 42 C.F.R. § 2.35.
21
Under 42 C.F.R. Part 2, a written consent to a disclosure under the regulation must include:
(1) the specific name or general designation of the program or person permitted to make
the disclosure;
(2) the name or title of the individual or the name of the organization to which
disclosure is made;
(3) the name of the patient;
(4) the purpose of the disclosure;
(5) how much and what kind of information is to be disclosed;
(6) the signature of the patient and, when required for a patient who is a minor, the
signature of the person who is authorized to give consent; or, when the patient is
incompetent or deceased, the signature of the person authorized to sign in lieu of the
patient;
(7) the date on which the consent is signed;
(8) a statement that the consent is subject to revocation at any time except to the extent
that the program or person which is to make the disclosure has already acted in
reliance on it (including providing treatment services in reliance on a valid consent to
disclose information to a third-party payer); and
(9) the date, event, or condition on which the consent will expire if not revoked before
(to ensure that the consent last no longer than reasonably necessary to serve the
purpose for the disclosure).
The regulation provides a sample consent form at 42 C.F.R. § 2.31.
Third party payers, administrative entities, and others85
The restrictions of 42 C.F.R. Part 2 on disclosures apply to:
(1) third party payers with regard to records disclosed to them by federally
assisted substance abuse programs;
(2) entities having direct administrative control over programs with regard to
information communicated to them by the program; and
(3) persons who receive patient records directly from a federally assisted
substance abuse program and who are notified of the restrictions on
redisclosure of the records.
                                      
85 42 C.F.R. § 2.12(d)(2).
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Minors86
Under 42 C.F.R. Part 2, the term “minor” means a person that has not attained majority
under the applicable state law (or, if no age of majority is specified in state law, eighteen years of
age).
If a minor acting alone has the capacity under applicable state law to enter into a substance
abuse program, then only the minor can give any written consent for disclosure under the
regulation.87
Where state law requires consent of a parent, guardian, or other person for a minor to obtain
substance abuse treatment, any written consent for disclosure must be given by both the minor and
his or her parent, guardian, or other person authorized to act on the minor’s behalf.88
In addition, where state law requires parental consent to treatment, the fact that a minor has
applied for treatment may be communicated to the minor’s parent, guardian, or other person
authorized to act on the minor’s behalf only if:
(1) the minor has given written consent to the disclosure; or
(2) the minor lacks capacity to make a rational choice regarding such consent because of
extreme youth or physical or mental condition, as judged by the program director.89
Prohibition on Redisclosure90
Every disclosure made with a patient’s written consent must by accompanied by the
following written statement:
This information has been disclosed to you from records protected by Federal
confidentiality rules (42 C.F.R. Part 2).  The Federal rules prohibit you from making
any further disclosure of this information unless further disclosure is expressly
permitted by the written consent of the person to whom it pertains or as otherwise
permitted by 42 C.F.R. Part 2.  A general authorization for the release of medical or
other information is NOT sufficient for this purpose.  The Federal rules restrict any
use of the information to criminally investigate or prosecute any alcohol or drug
abuse patient.
Permitted Uses and Disclosures Without Consent91
42 C.F.R. Part 2 permits federally assisted substance abuse programs to use and disclose
substance abuse records without a patient’s consent in the following situations:
                                      




90 42 C.F.R. § 2.32.
91 42 C.F.R. § 2.52.
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(1) to medical personnel In cases of medical emergencies;
(2) to FDA  medical  personnel who assert a reason to
believe that an individual may be harmed by an error in the manufacture,
labeling, or sale of a product under FDA jurisdiction (if the information is
used solely to notify patients or physicians of potential dangers);
(3) for medical research activities where the program director makes a
determination that the recipient of the information:
• is qualified to conduct the research;
• has a research protocol under which the information will be secured
and not redisclosed; and
• has provided a written statement that a group of three or more
independent individuals has reviewed the protocol and determined
that the rights and welfare of the patients will be adequately protected
and the risks of disclosure are outweighed by the potential benefits of
the research.
(4) to any person who conducts an audit or evaluation of the program on behalf
of
• any federal, state or local governmental agency that provides financial
assistance to the program or is authorized to regulate the program;
• third party payers covering patients in the program or peer review
organizations performing a utilization or quality review; or
• is determined by the director of the program to conduct audit or
evaluation activities.92  Records may not be copied or leave the premises
unless the person removing the records agrees, in writing, to secure the
records and destroy them upon completion of the audit or evaluation93;
and
(5) upon a court order compelling disclosure (see below).
Disclosure Under Court Order94
A substance abuse program may disclose a patient’s substance abuse records without the
patient’s consent upon a court order accompanied by a subpoena or other legal mandate compelling
disclosure.
                                      
92 42 C.F.R. §2.53(a).
93 42 C.F.R. §2.53(b).
94 42 C.F.R. §2.61.
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Court orders issued pursuant to 42 C.F.R. Part 2 are for a specific, limited purpose: to
authorize a program to disclose or use patient information that would otherwise be prohibited under
the rule.
42 C.F.R. Part 2 also provides that a court order may compel disclosure of a patient’s
confidential communications to a substance abuse program, but only if the disclosure is necessary
to:
(1) protect against an existing threat to life or of serious bodily injury (including child
abuse and neglect);
(2) investigate or prosecute an extremely serious crime (e.g., one that threatens life or
serious bodily injury, homicide, rape, kidnapping, armed robbery, or child abuse and
neglect); or
(3) litigate in a proceeding in which the patient offers testimony or other evidence
pertaining to the content of the confidential communications.95
Disclosure Standard96
Like the Privacy Rule, 42 C.F.R. Part 2 limits the amount of information that may be
disclosed.  Any disclosure made under 42 C.F.R. Part 2 must be limited to the information
“necessary to carry out the purpose of the disclosure.”
Exceptions97
42 C.F.R. Part 2 contains a number of exceptions to the general rule on substance abuse
records.  The rule does not apply to the following:
(1) information on alcohol and drug abuse patients maintained in connection with the
Veterans’ Administration (VA) provision of hospital care, nursing home care,
domiciliary care, and medical services (which are governed by separate VA
regulations);
(2) information obtained by any component of the armed forces during a period when
the patient was subject to the Uniform Code of Military Justice that is exchanged
within the armed forces or between the armed forces and components of the VA
furnishing health care to veterans;98
(3) communications of information between or among personnel having a need for the
information in connection with their duties that arise out of the provision of the
diagnosis, treatment, or referral for treatment of alcohol or drug abuse if the
communications are
                                      
95 42 C.F.R. §2.63.
96 42 C.F.R. §2.12(a).
9742 C.F.R. § 2.12(c).
98 The armed forces exception is limited to the exchanges noted (within the armed forces and between the armed forces
and the VA).  The regulations do apply to any other disclosure by the armed forces.  See 42 C.F.R. §2.12(c)(2).
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• within a program; or
• between a program and an entity that has direct administrative control over the
program.
(4) communications between a program and a qualified service organization of
information needed by the organization to provide services to the program;
(5) communications between program personnel and law enforcement officers that are
• directly related to a patient’s commission of a crime on the premises or against
program personnel (or the threat to commit such a crime); and
• are limited to the circumstances of the incident, including the patient status of
the individual committing or threatening to commit the crime, that individual’s
name and address, and that individual’s last known whereabouts; and
(6) reporting under state law of incidents of suspected child abuse and neglect to the
appropriate state or local authorities.
• The restrictions of 42 C.F.R. Part 2 continue to apply to the original alcohol or
drug abuse patient records maintained by the program, including their disclosure
and use for civil or criminal proceedings that may arise out of the report of
suspected child abuse and neglect.
In addition, the type of diagnosis a patient received affects whether or not 42 C.F.R. Part 2
applies to the patient’s record.  The regulation covers any record of a diagnosis identifying a patient
as an alcohol or drug abuse patient that is prepared in connection with the treatment or referral for
treatment for alcohol or drug abuse.99
42 C.F.R. Part 2 does not cover:
(1) a diagnosis made solely for the purpose of providing evidence for use by law
enforcement authorities; or
(2) a diagnosis of drug overdose or alcohol intoxication that clearly shows that the
individual involved does not suffer from substance abuse (e.g., involuntary ingestion
of alcohol or drugs or reaction to a prescribed dosage of one or more drugs).100
Restriction on Use:  Criminal Charges
42 C.F.R. Part 2 allows the disclosure or use of a patient’s records to conduct a criminal
investigation or initiate or substantiate criminal charges against a patient only if a court order
compels such use or disclosure.101  Without a court order, the restriction prohibits the introduction
                                      
99 42 C.F.R. § 2.12(e)(4).
100 Id.
101 42 C.F.R. § 2.12(a)(2).
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of the records into evidence in a criminal proceeding and any other use of the information to
investigate or prosecute a patient with respect to a suspected crime.102
Under the authorizing statute, a judge can issue a court order only for good cause, which
requires a judge to balance the public interest and the need for disclosure against the injury to the
patient, the physician-patient relationship, and to the treatment program.103  The statute also requires
a judge issuing such an order to impose appropriate safeguards to ensure against unauthorized
disclosure of the information.104
The restriction applies to any person who obtains information about a patient for purposes
of conducting a criminal investigation or initiating or substantiating criminal charges from a
program, regardless of the status of the recipient or of whether the information was obtained in
accordance with the regulation.105  Information obtained by undercover agents or informants or
through a patient’s access to the records is subject to this restriction.106
Security Standards
42 C.F.R. Part 2 requires programs to maintain substance abuse records subject to the
regulation in a secure room, in a locked file cabinet, safe or other similar container when the records
are not in use.  In addition, the regulation requires programs to adopt written procedures to regulate
access to and use of records subject to the regulation.107
These security standards are far easier to implement than the data security standards of the
Privacy Rule, which are the subject of an entirely separate regulation under HIPAA.
Rights of Patients
At the time a patient is admitted (or as soon after as the patient can communicate rationally),
a program must inform the patient that federal law and regulations protect the confidentiality of
alcohol and drug abuse patient records and provide a copy of the federal law and regulations to the
patient.108
The notice to the patient must contain
(1) a general description of the limited circumstances allowing disclosure;
(2) a statement that violation of the law and regulations is a crime and that suspected
violations may be reported to authorities;
(3) a statement that information related to a patient’s commission of a crime on the
premises is not protected;
                                      
102 Id.
103 42 U.S.C. §290ee-3(b)(2)(c).
104 Id.
105 42 C.F.R. § 2.12(d).
106 Id.
107 42 C.F.R. § 2.16.
108 42 C.F.R. § 2.12.
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(4) a statement that reports of suspected child abuse and neglect made under state law to
appropriate state or local authorities are not protected; and
(5) a citation to the federal law and regulations.109
The regulation provides a sample notice at 42 C.F.R. § 2.23.
42 C.F.R. Part 2 allows (but does not require) a program to provide a patient access to his or
her own records, including the opportunity to inspect and copy any records that the program
maintains about the patient.110  The patient’s consent or written authorization is not required.
This provision differs from the Privacy Rule, which requires that a patient be given access to
his or her own PHI (except for psychotherapy notes).111  Therefore, as a practical matter, substance
abuse programs will have to comply with the Privacy Rule, which makes patient access to his or her
own records a requirement rather than an option.
Relationship to State Laws112
42 C.F.R. Part 2 does not preempt all state law regarding the confidentiality of substance
abuse patient records.  If a state law prohibits a disclosure permitted by 42 C.F.R. Part 2, neither the
substance abuse confidentiality statute nor regulations authorize a violation of such a state law.
Therefore, more strict state confidentiality laws remain in place.  Similarly, no state law may
authorize or compel any disclosure that 42 C.F.R. Part 2 prohibits.
Interaction of the Privacy Rule with Confidentiality of Alcohol and Drug Abuse Patient
Record Rule
The preamble to the Privacy Rule discusses the Rule’s interaction with 42 C.F.R. Part
2.113  In many cases, the two sets of rules treat disclosures similarly.  For example, under
either set of rules, the patient may have access to his or her medical records.
In other cases, either the Privacy Rule or 42 C.F.R. Part 2 is more stringent in terms
of what disclosures are permitted.  For example, the Privacy Rule permits disclosures
without patient consent for public health activities and directory assistance.  These
disclosures would not be permissible under 42 C.F.R. Part 2.
In yet other cases, the Privacy Rule is more restrictive.  For example, 42 C.F.R. Part 2
permits disclosure without patient consent to the FDA and for medical research activities.114
The Privacy Rule restricts these types of disclosures and requires consent for them.  Since
neither set of rules requires disclosures that the other does not permit, there is no direct
conflict between the Privacy Rule and 42 C.F.R. Part 2, although the requirements of each
rule on any particular issue may not be obvious.
                                      
109 42 C.F.R. § 2.22.
110 42 C.F.R. § 2.23.
111 45 CFR § 164.526, 65 Fed. Reg. 82824-26 (Dec. 28, 2000).
112 42 C.F.R. § 2.20.
113 See 65 Fed. Reg. 82482, 82484 (Dec. 28, 2000).
114 See 42 C.F.R. §2.51.
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Providers that fall under both sets of rules must follow the more stringent set of
rules for any particular disclosure.  This will make implementation of the rules challenging
for most substance abuse providers.
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Crosswalk Between the Privacy Rule and 42 C.F.R. Part 2
The following chart highlights provisions of the Privacy Rule and 42 C.F.R. Part 2 and comments on the differences between the rules.
I s su e Privacy Rule 42 C.F.R. Part 2 Commentary
General Rule “Covered entities” may not use or disclose
“protected health information” (PHI) except
as authorized by the individual who is the
subject of the information, or as explicitly
required or permitted by the regulation, noted
below.
The rule restricts the disclosure or use of any
information, whether or not recorded, that
would identify a patient as a substance abuse
patient either directly, by reference to other
publicly available information, or through
verification of such identification by another
person.  Records may be disclosed only as
permitted by the regulation (described below)
and may not otherwise be disclosed or used in
any civil, criminal, administrative, or legislative
proceedings conducted by any federal, state, or
local authority.
The prohibition applies to information
obtained by a federally assisted alcohol or drug
abuse program for the purpose of treating
alcohol or drug abuse, making a diagnosis for
such treatment, or making a referral for such
treatment.
The Privacy Rule is much broader in its
general rule and applicability.  Whereas 42
C.F.R. Part 2 applies to substance abuse
records of federally assisted substance abuse
programs, the Privacy Rule applies to a
broader class of information held by covered
entities (which are defined below, but include
providers and insurers and other entities that




Even when the use or disclosure of PHI is
permitted, in most circumstances, only the
“minimum necessary” amount of information
to accomplish the intended purpose of the use,
disclosure or request may be provided.
42 C.F.R. Part 2 limits the amount of
information that may be disclosed.  Any
disclosure made under 42 C.F.R. Part 2 must
be limited to the information “necessary to
carry out the purpose of the disclosure.”
The provisions of the rules are similar.
As a practical matter, the “minimum
necessary” determination should begin with an
assessment of whether or not the intended use
or purpose could be accomplished by de-
identifying the data or using summary data,
rather than assuming that all protected health
information may be disclosed, and then
attempting to narrowing the scope of




The rule applies to all PHI maintained, used or
disclosed by a covered entity, regardless of the
form it takes – electronic, written or oral.
Applies to any information, whether recorded
or not, relating to a patient received or
acquired by a federally assisted alcohol or drug
The Privacy Rule applies to a broader scope of
information (all PHI) than 42 C.F.R. Part 2
(substance abuse records).
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This information remains protected during the
life of the individual, and information about a
deceased individual must remain protected as
long as the covered entity maintains the
information.
program.
The regulation applies whether or not the
person holding the information believes that
the person seeking the information already has
it, has other means of obtaining it, is a law
enforcement official or other official, or has a
subpoena, or any other justification for a
disclosure or use that is not permitted by 42
C.F.R. Part 2.
A program may not respond to requests to
acknowledge the presence of an identified
patient in a facility or part of a facility that is
publicly identified as a substance abuse facility
unless the patient consents in writing to such
acknowledgement or a court order compels
such acknowledgement.  Responses to such
requests for acknowledgement must be made
in a manner that does not reveal whether an
identified individual has been or is being
treated for substance abuse.
42 C.F.R. does not prohibit the disclosure of
patient identifying information related to cause
of death for purposes of laws requiring or
authorizing collection of vital statistics.
Exceptions to
Applicability
No specific exceptions like those contained in
42 C.F.R. Part 2, but the rule is limited to
covered entities and allows for certain
disclosures without a patient’s consent, noted
below.
42 C.F.R. Part 2 contains a number of
exceptions to the general rule on substance
abuse records.  The rule does not apply to the
following:
• information on alcohol and drug abuse
patients maintained in connection with
the Veterans’ Administration (VA)
provision of hospital care, nursing home
care, domiciliary care, and medical
services (which are governed by separate
VA regulations);
• information obtained by any component
42 C.F.R. Part 2 provides more explicit
exceptions than the Privacy Rule, which relies
more on what is a covered entity and the types
of disclosures permitted.
42 C.F.R. Part 2’s exceptions related to
treatment communications among personnel
are similar to the Privacy Rule’s provisions on
treatment, payment, and operations (TPO) for
which consent is required.   In that respect, the
Privacy Rule is stricter than 42 C.F.R. Part 2.
Similarly, 42 C.F.R. Part 2’s exceptions for
qualified service organizations are more
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of the armed forces during a period when
the patient was subject to the Uniform
Code of Military Justice that is exchanged
within the armed forces or between the
armed forces and components of the VA
furnishing health care to veterans;
• communications of information between
or among personnel having a need for the
information in connection with their
duties that arise out of the provision of
the diagnosis, treatment, or referral for
treatment of alcohol or drug abuse if the
communications are
1. within a program; or
2. between a program and an entity
that has direct administrative
control over the program.
• communications between a program and a
qualified service organization of
information needed by the organization to
provide services to the program;
• communications between program
personnel and law enforcement officers
that are
1. directly related to a patient’s
commission of a crime on the
premises or against program
personnel (or the threat to commit
such a crime); and
2. are limited to the circumstances of
the incident, including the patient
status of the individual committing or
threatening to commit the crime, that
individual’s name and address, and
that individual’s last known
whereabouts; and
relaxed than the Privacy Rule’s treatment of
communications with “business associates.”
42 C.F.R. Part 2 makes exceptions to
applicability for certain types of diagnosis.
The Privacy Rule makes no distinctions based
on type of diagnosis.
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3. reporting under state law of incidents
of suspected child abuse and neglect
to the appropriate state or local
authorities.
In addition, the type of diagnosis a patient
received affects whether or not 42 C.F.R. Part
2 applies to the patient’s record.  The
regulation covers any record of a diagnosis
identifying a patient as an alcohol or drug
abuse patient that is prepared in connection
with the treatment or referral for treatment for
alcohol or drug abuse.
42 C.F.R. Part 2 does not cover:
• a diagnosis made solely for the purpose of
providing evidence for use by law
enforcement authorities; or
• a diagnosis of drug overdose or alcohol
intoxication that clearly shows that the
individual involved does not suffer from
substance abuse (e.g., involuntary
ingestion of alcohol or drugs or reaction
to a prescribed dosage of one or more
drugs).
Key Definitions Covered entities
“Covered entities” are broadly defined.  The
term includes:
• A health plan;
• A health care clearinghouse; and
• A health care provider who transmits
health information in electronic form in
connection with transactions (i.e.,
exchanges of information) covered by
HIPAA’s administrative requirements
Federally Assisted
An alcohol or substance abuse program is
considered to be federally assisted under 42
C.F.R. Part 2 if it:
• receives Federal funds in any form (e.g.,
Medicare or Medicaid) for any purpose
(including purposes not related to alcohol
and drug treatment);
• holds Federal tax exempt status, 501 (c)(3)
tax exempt status, or allows for tax
deductions for contributions through the
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Health plan
A “health plan” means an individual or group
plan that provides, or pays the cost of, medical
care (as defined in §2791(a)(2) of the Public
Health Service Act (PHSA)). Health plans
include:
• Virtually all group health plans (insured or
self-insured) covered under the Employee
Retirement Income Security Act of 1974
(ERISA) (i.e, those group health plans
with 50 or more participants and plans of
any size that are administered by other
entities);
• Health insurance issuers (as defined by
HIPAA to include an insurance company,
insurance services, or insurance
organization (including a health
maintenance organization) that is licensed
to engage in the business of insurance in a
state and which is subject to state law
regulating insurance (within the meaning




• Medicare-supplemental policy issuers;
• An employee welfare benefit plan or any
other arrangement providing health
benefits to employees of two or more
employers;
• MEWAs (multiple employer welfare
arrangements);
• Health care programs for active military
personnel and veterans;
• CHAMPUS;
• The Indian Health Service;
• The Federal Employees Health Benefit
Program;
• Approved SCHIP programs;
deductions for contributions through the
Internal Revenue Service.
• is conducted directly by the Federal
government (e.g., an Federal agency’s
employee assistance program);
• a state or local government which receives
Federal funds that may or may not
necessarily be spent for alcohol or drug
abuse programs;
• receives SAPT grant funds that may or
may not be supplemented by State or local
funds; and
• a program carried out under licensure,
certification, registration or authorization
by any federal agency (e.g., provider status
under Medicare or registration to dispense
controlled substances).
Substance Abuse Program
Coverage includes, but is not limited to,
treatment and rehabilitation programs,
employee assistance programs, programs
within general hospitals, school-based
programs, and private practitioners that hold
themselves out as providing, and that do
provide, alcohol or drug abuse diagnosis,
treatment, or referral for treatment.
Disclose or Disclosure
A communication of patient identifying
information, the affirmative verification of
another person’s communication of patient
identifying information, or the communication
of any information from the record of a
patient who has been identified.
Patient
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• Medicare +Choice plans; and
• State high-risk pools.
Health care clearinghouse
“Health care clearinghouses” are public or
private entities (including billing companies or
community health management information
systems) that either (1) process or facilitate
processing of health information received
from another entity in a nonstandard format
into standard data elements or a standard
transaction; or (2) receive a standard
transaction from another entity and process or
facilitate processing of health information into
a nonstandard format or nonstandard data
content for the receiving entity.
Health care provider
“Health care providers” are providers of
medical or health services and any other
person or organization that furnishes, bills or
is paid for health care in the normal course of
business.
Health care
“Health care” includes preventive, diagnostic,
therapeutic, rehabilitative, maintenance, or
palliative care.  It also includes counseling,
service, assessment, or other procedure with
respect to the physical or mental condition (or
functional status) of an individual or that
affects the structure or function of the body.
Protected health information (PHI)
“Protected health information (PHI)” means
individually identifiable health information that
is transmitted or maintained by electronic
di i i d i i i
Any individual who has applied for, or has
been given, a diagnosis for treatment for
alcohol or drug abuse at a federally assisted
program.  This includes any individual who,
after arrest on a criminal charge, is identified as
an individual with a potential alcohol or drug
abuse program in order to determine the
individual’s eligibility to participate in a
treatment program.
Qualified Service Organization
A person or any entity (including corporations
and government agencies) that provides
services to a program, such as data processing,
bill collecting, dosage preparation, laboratory
analysis, or legal, medical, accounting, or other
professional services, or services to prevent or
treat child abuse or neglect that:
1. has entered into a written agreement with
a program under which the person or
entity:
• acknowledges that in receiving, storing,
processing or otherwise dealing with any
patient records from the program, it is
fully bound by 42 C.F.R. Part 2; and if
necessary, will resist in judicial
proceedings any efforts to obtain access
to patient records except as permitted by
42 C.F.R. Part 2.
Records
Any information, whether recorded or not,
relating to a patient received or acquired by a
federally assisted alcohol or drug program.
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media or is transmitted or maintain in any
other form or medium.
“Health information” is any information
(whether oral or recorded in any form or
medium) that is created or received by a health
care provider, health plan, public heath
authority, employer, life insurer, school or
university, or health care clearinghouse and
relates to the past, present or future physical or
mental health or condition of an individual, the
provision of health care to an individual or the
past, present or future payment for the
provision of health care to an individual.  This
definition reflects the broad category of
information governed by the administrative
simplification provisions of HIPAA.
“Individually identifiable health information”
is a subset of “health information.”  It is health
information that either actually identifies the
individual or creates a reasonable basis to
believe that the information would identify the
individual.
As defined above, PHI is a subset of
individually identifiable health information.
Note that the protections described below
apply to data or information about an
individual, not to any particular record.
However, once the privacy protections attach
to data, the transmitter and receiver of the data
must protect every record (written, electronic
or other) in which the data appears.
Patient Identifying Information
The name, address, social security number,
fingerprints, photograph, or similar
information by which the identity of a patient
can be determined with reasonable accuracy
and speed either directly or with reference to
other publicly available information.  The term
does not include a number assigned to a patient
by a program, if that number does not consist
of, or contain numbers (such as social security,
or driver’s license number) that could be used
to identify a patient with reasonable accuracy





Permitted uses and disclosures
The rule permits use or disclosure of PHI only
in the following circumstances:
• To the patient (required disclosure if
Permitted Disclosures With Patient Consent & Form
of Consent
A program may disclosure a patient’s records
with the patient’s written consent to any
individual or organization named in the
The Privacy Rule permits disclosures
without patient consent in several
instances, such as public health
activities and directory assistance,
that would not be permissible under
42 C.F.R. Part 2.
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requested);
• Pursuant to a valid consent by the patient
that meets the requirements of the
regulation to carry out treatment, payment
or health care operations;
• Pursuant to a valid authorization by the
patient that meets the requirements of
the regulation;
• Pursuant to an agreement under, or as
otherwise permitted by, the regulation; or
• As explicitly permitted or required by the
regulation (e.g., to the Secretary of HHS
for purposes of determining compliance
with the rule).
consent.
A program may also disclose patient records to
a central registry or to any detoxification or
maintenance treatment program within 200
miles for the purpose of preventing multiple
enrollment of the patient.  Such a disclosure
requires a patient’s written consent.  The
disclosure may be made when:
1. the disclosure is made when the patient is
accepted for treatment;
2. the type or dosage of the drug is changed;
or
3. the treatment is interrupted, resumed, or
terminated.
Such a disclosure must be limited to the
patient’s identifying information, the type and
dosage of the drug, and relevant dates.  A
central registry or detoxification program can
use the information only for the purpose of
preventing multiple enrollments, and cannot
redisclose the information or use the
information for any other purpose unless
authorized by a court order.
A program may also disclose information
about a patient to elements of the criminal
justice system that have referred patients to the
program and made the patient’s participation
in the program a condition of the disposition
of any criminal proceedings.  Such a disclosure
can be made if (1) it is made only to the
individuals within the criminal justice system
that need the information in connection with
their duty to monitor the patient’s progress
(e.g., probation or parole officers); and (2) the
patient has signed a written consent for the
disclosure.
In other cases, the Privacy Rule is more
restrictive.  42 C.F.R. Part 2 permits disclosure
without patient consent to the FDA and for
medical research activities.  The Privacy Rule
restricts these types of disclosures and requires
consent for them.
Since neither set of rules requires disclosures
that the other does not permit, there is no
direct conflict between the Privacy Rule and 42
C.F.R. Part 2, although the requirements of
each rule on any particular issue may not be
obvious.
An exhaustive list of each rule’s treatment of
every potential disclosure is beyond the scope
of this chart.  As a practical matter, however,
whenever a particular disclosure is in question,
a provider should check both sets of rules to
determine which is more stringent, and follow




The Privacy Rule allows a consent document
to be “brief and may be written in general
terms.  It must be written in plain language,
inform the individual that the information may
be used and disclosed for TPO, state the
patient’s rights to review the providers’ privacy
notice, to request restrictions and to revoke
consent, and be dated and signed by the
individual (or his or her representative).”
The Privacy Rule’s requirement for an
authorization is more specific.  To be valid, an
authorization by the individual must:
• Describe the information to be used or
disclosed in a specific and meaningful
fashion;
• Name the person or class of persons
authorized to make the disclosure or use;
• Name the person or class of persons to
whom the disclosure may be made;
• Contain an expiration date that relates to
the individual or to the purpose of the
disclosure or use;
• Clearly state that the individual has a right
to revoke the authorization in writing (and
describe the procedure for doing so) as
well as any exemptions to the right to
revoke;
• Be signed by the individual (or the
individual’s personal representative) and
dated.
The individual must be given a copy of the
signed authorization.
If a covered entity initiates the request for
authorization or disclosure (rather than the
individual), additional requirements apply.
Under 42 C.F.R. Part 2, a written consent to a
disclosure under the regulation must include:
(10) specific name or general designation
of the program or person permitted
to make the disclosure;
(11) name or title of the individual or the
name of the organization to which
disclosure is made;
(12) name of the patient;
(13) purpose of the disclosure;
(14) how much and what kind of
information is to be disclosed;
(15) signature of the patient and, when
required for a patient who is a minor,
the signature of the person who is
authorized to give consent; or, when
the patient is incompetent or
deceased, the signature of the person
authorized to sign in lieu of the
patient;
(16) the date on which the consent is
signed;
(17) a statement that the consent is
subject to revocation at any time
except to the extent that the program
or person which is to make the
disclosure has already acted in
reliance on it (including providing
treatment services in reliance on a
valid consent to disclose information
to a third-party payer); and
(18) the date, event, or condition on
42 C.F.R. provides more detailed guidance on
what a valid consent must require, although
the Privacy Rule’s authorization requirements
are quite specific.
42 C.F.R. Part 2 also provides a sample
consent form (the Privacy Rule does not
provide any example).
As a practical matter, providers should develop
consent and authorization forms that comply
with both requirements simultaneously, which
is possible because the form of
consent/authorization under either rule is
similar and does not conflict with the other.
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which the consent will expire if not
revoked before (to ensure that the
consent last no longer than
reasonably necessary to serve the
purpose for the disclosure).
The regulation provides a sample consent
form at 42 C.F.R. § 2.31.
Consent v.
Authorization
“Consent” refers to a broad general
permission granted by the individual to a
health care provider or other covered entity to
use or disclose the individual’s PHI for
treatment, payment or health care operations
purposes.
In contrast, an “authorization” refers to a
more specific and detailed permission given to
No distinction. The Privacy Rule draws a distinction between
consent and authorization that is not
contained in 42 C.F.R. Part 2 because the
privacy rule contemplates different uses (such
as TPO) that 42 C.F.R. either addresses as
exceptions or allows only with consent.  The
broad nature of “consent” under the Privacy
Rule and the narrow nature of “authorization”
are collapsed into singular treatment as
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a covered or non-covered entity or business
partner by an individual to share an
individual’s PHI about issues other than
treatment, payment, and healthcare operations.
All covered entities, including health insurers,
providers, health care clearinghouses are
required to obtain authorization for the
disclosure of PHI for purposes other than
routine operations.
consent by 42 C.F.R. Part 2.
Prohibition on
Redisclosure
The Privacy Rule applies to recipients of PHI, Every disclosure made with a patient’s written
consent must by accompanied by the following
written statement:
This information has been disclosed to you
from records protected by Federal
confidentiality rules (42 C.F.R. Part 2).  The
Federal rules prohibit you from making any
further disclosure of this information unless
further disclosure is expressly permitted by the
written consent of the person to whom it
pertains or as otherwise permitted by 42 C.F.R.
Part 2.  A general authorization for the release
of medical or other information is NOT
sufficient for this purpose.  The Federal rules
restrict any use of the information to
criminally investigate or prosecute any alcohol
or drug abuse patient.
The Privacy Rule does not require any written
statement on redisclosure like the one required
by 42 C.F.R. Part 2 (although the Privacy Rule
does require certain language in business







Permits covered entities to use or disclose PHI
for TPO.
Consent required before a covered health
provider that has a direct treatment
relationship can use or disclose PHI for TPO.
42 C.F.R. Part 2 makes an exception for
certain treatment, payment, and operations
communications (see applicability, above)
The Privacy Rule is stricter in its requirement
that an initial consent be given for TPO.  42
C.F.R. Part 2 provides for an exception that
allows use or disclosure for certain treatment,






Consent is necessary for use or disclosure for
TPO unless the provider:
• has an indirect treatment relationship with
the individual,
• is providing health care to an inmate,
42 C.F.R. Part 2 contains exceptions for
certain treatment, payment, and operations
purposes (see applicability/exceptions above).
See 42 C.F.R. Part 2’s exceptions for certain
treatment, payment, and operations purposes.
40
• is in an emergency treatment situation
(but then the provider must attempt to
obtain consent as soon as practicable after
the treatment is delivered), is required by
law to obtain consent but unable to do so,







Unless otherwise specified under the
regulation, a covered entity may only use or
disclose PHI when it receives a valid
authorization by an individual.  Any use or
disclosure of PHI must be consistent with the
authorization.
Covered by general consent requirements. 42 C.F.R. does not make the “non-routine
operations” distinction.  42 C.F.R. Part 2




Covered entities are required to disclose PHI
regarding an individual only in two instances:
(1) to the individual who is the subject of the
PHI when the individual requests it, and (2) to
the Secretary of Health and Human Services
when the Secretary is investigating a complaint
or determining a covered entity’s compliance
with the regulation.
None, unless by court order. The Privacy Rule provides greater patient
protection by requiring disclosure to the






The Privacy Rule permits disclosure without
patient consent:
(1) to the extent that the disclosure is
required by law and the use or
disclosure complies with and is limited
to the relevant requirements of that
law;
(2) for certain public health activities.
These might include disclosure to:
• a public health authority authorized
by law to collect information to
prevent or control disease or conduct
public health surveillance;
• a public health authority empowered
by law to receive reports of child
abuse or neglect;
• under certain circumstances, to a
person subject to the jurisdiction of
42 C.F.R. Part 2 permits federally assisted
substance abuse programs to use and disclose
substance abuse records without a patient’s
consent in the following situations:
(6) to medical personnel In cases of
medical emergencies;
(7) to FDA  medical  personnel who
assert a reason to believe that an
individual may be harmed by an error
in the manufacture, labeling, or sale
of a product under FDA jurisdiction
(if the information is used solely to
notify patients or physicians of
potential dangers);
(8) for medical research activities where
the program director makes a
determination that the recipient of
As noted above, the Privacy Rule permits
certain disclosures (e.g., for public health
activities) that 42 C.F.R. Part 2 does not
permit.  Providers must check any potential
disclosure against the requirements of each
rule.
42 C.F.R. Part 2 is more explicit in detailing
disclosures under court order than the Privacy
Rule.  As a practical matter, providers faced
with a subpoena or court order compelling
disclosure should check the order and
purposes for the disclosure against each rule.
42 C.F.R. Part 2 is likely to be stricter on
disclosure under these circumstances.
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the Food and Drug Administration
(FDA);
• a person exposed to a communicable
disease; or
• in certain circumstances, an employer
regarding workplace-related medical
surveillance activities.
(3) to a government authority authorized
by law when the covered entity
reasonably believes that an individual
is a victim or abuse, neglect or
domestic violence;
(4) for health oversight activities
authorized by law, including, for
instance, fraud and abuse audits,
investigations, and civil,
administrative, or criminal
proceedings (except if the
investigation or other activities does
not arise out of and is not directly
related to the receipt of health care or
qualification or receipt of public
health benefits or services);
(5) for judicial and administrative
proceedings under certain
circumstances;
(6) for law enforcement purposes to a
law enforcement official.  However,
under this exception, only limited
information may be disclosed for
identification and location purposes,
such as information about an
individual who is a victim of a crime
when the victim has agreed to the
disclosure or when reporting a crime
in an emergency;
the information:
• is qualified to conduct the
research;
• has a research protocol under
which the information will be
secured and not redisclosed; and
• has provided a written statement
that a group of three or more
independent individuals has
reviewed the protocol and
determined that the rights and
welfare of the patients will be
adequately protected and the
risks of disclosure are
outweighed by the potential
benefits of the research.
(9) to any person who conducts an
audit or evaluation of the program
on behalf of
• any federal, state or local governmental
agency that provides financial assistance
to the program or is authorized to regulate
the program;
• third party payers covering patients in the
program or peer review organizations
performing a utilization or quality review;
or
• is determined by the director of the
program to conduct audit or evaluation
activities.  Records may not be copied or
leave the premises unless the person
removing the records agrees, in writing, to
secure the records and destroy them upon
completion of the audit or evaluation; and
(10) upon a court order compelling
disclosure (see below)
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(7) to organ procurement organizations
regarding cadaver organs, eyes, or
tissue for donation purposes;
(8) for research purposes provided that
an Institutional Review Board (IRB)
or privacy board (as described in
§164.512(i)(B) of the regulation)
approves the waiver of individual
authorization required under
§164.508 of the regulation and certain
other conditions are met;
(9) to avert a serious threat to health or
safety;
(10) for specialized government functions,
such as separation or discharge from
the military, to determine eligibility
for veterans’ health benefits, or for
protective services for the President
and others;
(11) to the extent necessary to comply
with workers’ compensation or other
similar laws. Note that the exception
permitting disclosure applies only
when providing the information is
required under these laws, not when
the laws simply permit disclosure.
disclosure (see below).
Disclosure Under Court Order
A substance abuse program may disclose a
patient’s substance abuse records without the
patient’s consent upon a court order
accompanied by a subpoena or other legal
mandate compelling disclosure.
Court orders issued pursuant to 42 C.F.R. Part
2 are for a specific, limited purpose: to
authorize a program to disclose or use patient
information that would otherwise be
prohibited under the rule.
42 C.F.R. Part 2 also provides that a court
order may compel disclosure of a patient’s
confidential communications to a substance
abuse program, but only if the disclosure is
necessary to:
(4) protect against an existing threat to
life or of serious bodily injury
(including child abuse and neglect);
(5) investigate or prosecute an extremely
serious crime (e.g., one that threatens
life or serious bodily injury, homicide,
rape, kidnapping, armed robbery, or
child abuse and neglect); or
(6) litigate in a proceeding in which the
patient offers testimony or other





The Privacy Rule also applies to transactions
between covered entities and their “business
associates.”  Business associates are defined as
those who perform or assist in the
performance by a covered entity of:
(3) a function or activity involving the use or
disclosure of individually identifiable
health information (including claims
processing or administration, data
analysis, quality assurance, billing, benefit
management);
(4) a function or activity regulated by
HIPAA.
Business associates are persons who provide
certain services to or on behalf of the covered
entity, including legal, actuarial, accounting,
consulting, data aggregation, management,
administrative, accreditation or financial
services.
Generally speaking, covered entities may only
share information with business associates
pursuant to a contract that limits the use and
disclosure of protected health information
(PHI) under the same restrictions that apply to
the covered entity.
A contract between a covered entity and its
business associate(s) must meet the
requirements of §164.504((e)(2) or (e)(3).
Among other things, this contract must:
(3) set out the permitted and required uses
and disclosures of PHI by the business
associate;
(4) provide that the business associate will:
42 C.F.R. Part 2 also applies to “qualified
service organizations,” the definition of which
is repeated here:
Qualified Service Organization
A person or any entity (including corporations
and government agencies) that provides
services to a program, such as data processing,
bill collecting, dosage preparation, laboratory
analysis, or legal, medical, accounting, or other
professional services, or services to prevent or
treat child abuse or neglect that:
1. has entered into a written agreement
with a program under which the
person or entity:
• acknowledges that in receiving,
storing, processing or otherwise
dealing with any patient records from
the program, it is fully bound by 42
C.F.R. Part 2; and if necessary, will
resist in judicial proceedings any
efforts to obtain access to patient
records except as permitted by 42
C.F.R. Part 2.
Third party payers, administrative entities, and others
The restrictions of 42 C.F.R. Part 2 on
disclosures apply to:
1. third party payers with regard to records
disclosed to them by federally assisted
substance abuse programs;
2. entities having direct administrative
control over programs with regard to
information communicated to them by
the program; and
The rules are similar in coverage of
organizations that provide services to “covered
entities” (Privacy Rule) or substance abuse
programs (42 C.F.R. Part 2).
As a practical matter, providers and covered
entities must review the relationships they have
with entities with which they share
information, to ensure compliance with both
sets of rules.
44
(f) not use or further disclose PHI except as
permitted by the regulation;
(g) use appropriate safeguards to assure the
proper use of PHI;
(h) report to the covered entity any
inappropriate or non-contractually agreed
upon use of PHI of which it becomes
aware;
(i) ensure that its employees, agents, and
subcontractors agree to the same
restrictions that are imposed on the
business associate; and
(j) permit the Secretary and the covered
entity access for audit purposes to its
internal practices, books and records
relating to the use or disclosure of PHI.
If the covered entity and its business
associate(s) are both governmental entities,
these requirements can be satisfied through a
Memorandum of Understanding, rather than a
contract.
3. persons who receive patient records
directly from a federally assisted substance
abuse program and who are notified of




The Privacy Rule affords new rights to
individuals regarding access to their own PHI.
For instance, individuals have a right to:
• inspect and obtain a copy of all PHI
relating to the individual;
• amend and/or correct that PHI;
• with certain exceptions, an accounting of
the uses and disclosure of their PHI (i.e.,
to know when and to whom disclosure
has been made for purposes other than
treatment, payment and health operations,
including disclosures made by or to a
business associate); this right applies to
disclosures made in the six (6) year period
At the time a patient is admitted (or as soon
after as the patient can communicate
rationally), a program must inform the patient
that federal law and regulations protect the
confidentiality of alcohol and drug abuse
patient records and provide a copy of the
federal law and regulations to the patient.
The notice to the patient must contain
(6) a general description of the
limited circumstances
allowing disclosure;
(7) a statement that violation of
the law and regulations is a
42 C.F.R. Part 2 and the Privacy Rule differ on
a patient’s access to his or her own records.  42
C.F.R. Part 2 allows, but does not require, that
the patient be given access.  In contrast, the
Privacy Rule requires that a patient be given
access to his or her own PHI (except for
psychotherapy notes).
Therefore, as a practical matter, substance
abuse programs will have to comply with the
Privacy Rule, which makes patient access to his
or her own records a requirement rather than
an option.
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prior to the request for an accounting;
• notice and a full description of the
covered entity’s use and disclosure
practices (generally any use or disclosure
of PHI not described in this notice is
prohibited); and
• challenge the covered entity’s use or
disclosure of PHI through complaints to
(1) the privacy official designated by each
covered entity and through the complaint
process that must also be established or
(2) to the Secretary of HHS through a
process that the Secretary will establish.
crime and that suspected
violations may be reported
to authorities;
(8) a statement that information
related to a patient’s
commission of a crime on
the premises is not
protected;
(9) a statement that reports of
suspected child abuse and
neglect made under state
law to appropriate state or
local authorities are not
protected; and
(10) a citation to the federal law
and regulations.
The regulation provides a sample notice at 42
C.F.R. § 2.23.
42 C.F.R. Part 2 allows (but does not require) a
program to provide a patient access to his or
her own records, including the opportunity to
inspect and copy any records that the program
maintains about the patient.  The patient’s






Does not preempt state statutes that have
more stringent privacy protections.
“More stringent” state laws are defined in the
regulation as those that are more protective of
an individual’s right to privacy protection for
his or her PHI, including those state laws
providing for greater rights of access or
amendment to individuals or prohibiting or
restricting a disclosure or use under
circumstances in which the Privacy Rule
permits it.
42 C.F.R. Part 2 does not preempt all state law
regarding the confidentiality of substance
abuse patient records.  If a state law prohibits a
disclosure permitted by 42 C.F.R. Part 2,
neither the substance abuse confidentiality
statute nor regulations authorize a violation of
such a state law.  Therefore, more strict state
confidentiality laws remain in place.  Similarly,
no state law may authorize or compel any
disclosure that 42 C.F.R. Part 2 prohibits.









The Privacy Rule allows covered entities to use
or disclose PHI without consent or
authorization if the covered entity reasonably
believes the patient is a victim of abuse,
neglect, or domestic violence.  The rule covers
child abuse and other victims of abuse, neglect
or domestic violence (e.g., abuse of nursing
home residents or residents of facilities for the
mentally retarded).
Covered entities can make such disclosures
only to a government authority, including a
social service or protective services agency,
authorized by law to receive reports of such
abuse, neglect, or domestic violence.  The
disclosure can be made only if:
• the disclosure is required by law and
complies with and is limited to the
relevant requirements of such law;  or
• if the individual agrees to the disclosure;
or
• to the extent the disclosure is expressly
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authorized by statute or regulation and
3. the covered entity, in its professional
judgment, believes the disclosure is
necessary to prevent serious harm to the
individual or other potential victims; or
4. if the individual is unable to agree because
of incapacity, a law enforcement or other
public official authorized to receive the
report represents that the PHI sought is
not intended for use against the individual
and that an immediate enforcement
activity that depends upon the disclosure
would be materially and adversely affected
by waiting until the individual is able to
agree to the disclosure.
Once the covered entity discloses the PHI, it
must promptly inform the individual that a
report has been made, unless:
• the covered entity, in the exercise of
professional judgment, believes that
informing the individual would place the
individual at risk of serious harm; or
• the covered entity would be informing a
personal representative, and the covered
entity reasonably believes the personal
representative is responsible for the abuse,
neglect, or other injury, and that
informing the representative would not be
in the best interests of the individual.
Applicability to
Minors
HHS’s guidance on the Privacy Rule indicates
that a parent with authority to make health
care decisions for the minor is generally a
“personal representative” of his or her minor
child under the Rule and has the right to
obtain access to health information about his
or her minor child.
Minors
Under 42 C.F.R. Part 2, the term “minor”
means a person that has not attained majority
under the applicable state law (or, if no age of
majority is specified in state law, eighteen years
of age).
Although the provisions are generally similar
and depend on provisions of state or other
law, the Privacy Rule affords more discretion
in confidential treatment relationships between
minors and providers.  42 C.F.R. Part 2’s
treatment depends solely on whether state law
requires parental consent, but the Privacy Rule
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There are exceptions to this general rule, in
which a parent might not be the “personal
representative” with respect to certain health
information.  In the following situations, the
rule defers to determinations under other law
that the parent does not control the minor’s
health care decisions and, thus, does not
control the PHI related to that care:
1. When state or other law does not require
consent of a parent or other person
before a minor can obtain a particular
health care services, and the minor
consents to the health care services, the
parent is not the minor’s personal
representative under the Privacy Rule.
For example, when a state law provides an
adolescent the right to consent to mental
health treatment without the consent of
his or her parent, and the adolescent
obtains such treatment without the
consent of the parent, the parent is not
the personal representative of the minor
under the Privacy Rule for that treatment.
The minor may choose to involve a
parent in the treatment decisions without
giving up his or her right to control the
PHI related to the treatment.
2. When a court determines or other law
authorizes someone other than the parent
to make treatment decisions for a minor,
the parent is not the personal
representative of the minor for the
relevant services.
For example, the Privacy Rule “reflects current
professional practice” in determining that the
parent is not the minor’s personal
representative with respect to the relevant
PHI:
If a minor acting alone has the capacity under
applicable state law to enter into a substance
abuse program, then only the minor can give
any written consent for disclosure under the
regulation.
Where state law requires consent of a parent,
guardian, or other person for a minor to
obtain substance abuse treatment, any written
consent for disclosure must be given by both
the minor and his or her parent, guardian, or
other person authorized to act on the minor’s
behalf.
In addition, where state law requires parental
consent to treatment, the fact that a minor has
applied for treatment may be communicated to
the minor’s parent, guardian, or other person
authorized to act on the minor’s behalf only if:
1. the minor has given written consent to the
disclosure; or
2. the minor lacks capacity to make a
rational choice regarding such consent
because of extreme youth or physical or
mental condition, as judged by the
program director.
allows for additional protections for minors.
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1. When a parent agrees to a confidential
relationship between a minor and a
physician, the parent does not have access
to the PHI related to that relationship.
2. When a physician or other covered entity
reasonably believes that the child has been
or may be subjected to abuse or neglect,
or that treating the parent as the child’s
personal representative could endanger
the child, the covered entity may choose




The Privacy Rule permits disclosures without
consent to law enforcement officials.
42 C.F.R. Part 2 allows the disclosure or use of
a patient’s records to conduct a criminal
investigation or initiate or substantiate criminal
charges against a patient only if a court order
compels such use or disclosure.  Without a
court order, the restriction prohibits the
introduction of the records into evidence in a
criminal proceeding and any other use of the
information to investigate or prosecute a
patient with respect to a suspected crime.
Under the authorizing statute, a judge can
issue a court order only for good cause, which
requires a judge to balance the public interest
and the need for disclosure against the injury
to the patient, the physician-patient
relationship, and to the treatment program.
The statute also requires a judge issuing such
an order to impose appropriate safeguards to
ensure against unauthorized disclosure of the
information.
The restriction applies to any person who
obtains information about a patient for
purposes of conducting a criminal
investigation or initiating or substantiating
criminal charges from a program, regardless of
The provisions of 42 C.F.R. Part 2 are stricter.
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the status of the recipient or of whether the
information was obtained in accordance with
the regulation.  Information obtained by
undercover agents or informants or through a







The privacy rule treats psychotherapy notes as
a distinct category of PHI.  With a few
exceptions, covered entities must obtain an
individual’s authorization to use or disclose
psychotherapy notes to carry out treatment,
payment, or health care operations.  As a
practical matter, such authorizations will rarely
be necessary, since, as the preamble to the rule
points out, psychotherapy notes do not include
information that covered entities typically need
for treatment, payment, or other routine health
care operations.
A covered entity must obtain the patient’s
consent (but not authorization) for the person
who created the psychotherapy notes to use
the notes to carry out treatment and for the
covered entity to use or disclose
psychotherapy notes for conducting training
programs in which students, trainees, or
practitioners in mental health learn under
supervision to improve their skills in
counseling.
A covered entity may also use psychotherapy
notes to defend a legal action or other
proceeding brought by the individual pursuant
to a consent (but without a specific
authorization).  This would allow disclosure to
the covered entity’s attorney to defend against
the action or proceeding, but disclosure to
others during the judicial or administrative
proceeding is governed by 45 C.F.R. §
164.512(e) (which describes court orders
compelling discovery of the notes, etc.).  The
42 C.F.R. Part 2 does not specifically address
substance abuse paraprofessionals, but if they
worked as part of a substance abuse program
covered by the rule, they would be subject to
its requirements.
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rule’s preamble notes that disclosure to a
covered entity’s attorney only requires consent
because the defense constitutes “health care
operations” and the entity should be able to
defend itself without seeking a specific
authorization from the patient.
The rule does not explicitly address
psychotherapy paraprofessionals.  The rule’s
broad definition, however, suggests that notes
of paraprofessionals are treated similarly to
those of any other provider who is a mental
health professional:
Notes recorded (in any medium) by a health care
provider who is a mental health professional
documenting or analyzing the contents of a
conversation during a private counseling
session or a group, joint, or family counseling
session and that are separated from the rest of
the individual’s medical record.  Psychotherapy
notes excludes medication prescription and
monitoring, counseling session start and stop
times, the modalities and frequencies of
treatment furnished, results of clinical tests,
and any summary of the following items:
diagnosis, functional status, the treatment plan,
symptoms, prognosis, and progress to date.
Data Security
Standards
As part of HIPAA’s administrative
simplification, HHS promulgated extensive
electronic security standards.  See 65 Fed. Reg.
50311 (Aug. 17, 2000)/
42 C.F.R. Part 2 requires programs to
maintain substance abuse records subject to
the regulation in a secure room, in a locked file
cabinet, safe or other similar container when
the records are not in use.  In addition, the
regulation requires programs to adopt written
procedures to regulate access to and use of
records subject to the regulation.
2 C.F.R. Part 2’s security standards are far easier
o implement than the data security standards of
he Privacy Rule, which are the subject of an
ntirely separate regulation under HIPAA.
Enforcement and The Secretary of HHS delegated the Any person violating 42 C.F.R. Part 2 or its The penalties for violation of the Privacy Rule
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Compliance enforcement of the Privacy Rule to HHS’s
Office of Civil Rights.  Through that office,
the Secretary of HHS can bring enforcement
actions against covered entities.  Under
HIPAA, the Secretary may impose civil
monetary penalties of not more than $100 per
person per violation and up to $25,000 for
violations of a single standard within a single
calendar year.  In addition, criminal penalties
are established under HIPAA for wrongful
disclosures of PHI, which, upon conviction,
could result in fines of not more than $50,000
and/or imprisonment for not more than one
year.  Offenses committed with intent to sell,
transfer or use PHI for commercial or
personal gain or malicious harm are punishable
by a fine not to exceed $250,000 and/or 10-
year imprisonment.
The Privacy Rule does not authorize private
rights of action for wrongful disclosure
violations.  However, individuals may report
violations to the Secretary so HHS can
undertake appropriate investigation and
enforcement activities on behalf of an
aggrieved individual.
Under the rule, providers have until April 14,
2003 to come into compliance (and small
health plans with less than five million in
revenues have an additional year).
implementing statutes can be fined up to $500
for the first offense, and up to $5,000 for each
subsequent offense.
are more severe (higher monetary penalties
and potential jail time) than the penalties for
violating 42 C.F.R. Part 2.
